We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: GVHD
MedXY News
EnglishTag

GVHD

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Regulatory-like FOXP3+Helios+CD4+ T Conventional Cells Correlate with T-Cell Activation After Orca-T Immunotherapy
Hematology-OncologyAllo-HSCTBệnh Bạch Cầu Tế Bào Phôi

Regulatory-like FOXP3+Helios+CD4+ T Conventional Cells Correlate with T-Cell Activation After Orca-T Immunotherapy

By MedXY|May 29, 2026

A study of leukemia patients found that Orca-T transplant therapy increases a regulatory-like CD4+FOXP3+Helios+ T-cell subset early after treatment, and this subset correlates with later T-cell activation, offering a potential biomarker for

Precision T-Cell Engineering in AlloHSCT: The Orca-T Revolution and the Precision-T Phase 3 Results
Clinical UpdatesAlloHSCT
GVHD

Precision T-Cell Engineering in AlloHSCT: The Orca-T Revolution and the Precision-T Phase 3 Results

By MedXY|Mar 20, 2026

This review analyzes the Phase 3 Precision-T trial, demonstrating that Orca-T, a high-precision T-cell therapy, significantly improves chronic GVHD-free survival and reduces non-relapse mortality compared to standard-of-care prophylaxis in

Post‑transplant Cyclophosphamide with Sirolimus/Cyclosporine Dramatically Lowers Chronic GVHD After Unrelated Donor PBSC Transplant Without Raising Relapse Risk
Hematology-OncologyGVHDposttransplant cyclophosphamide

Post‑transplant Cyclophosphamide with Sirolimus/Cyclosporine Dramatically Lowers Chronic GVHD After Unrelated Donor PBSC Transplant Without Raising Relapse Risk

By MedXY|Dec 10, 2025

In a randomized Phase II trial, replacing MMF with post‑transplant cyclophosphamide (PTCy) alongside sirolimus and cyclosporine in unrelated donor PBSC transplants markedly lowered chronic GVHD and improved 1‑year chronic GVHD‑free relapse‑

Advances in Graft-versus-Host Disease Prophylaxis: Cyclophosphamide and Cyclosporin in Allogeneic Stem Cell Transplantation
Clinical UpdatescyclophosphamideGVHD

Advances in Graft-versus-Host Disease Prophylaxis: Cyclophosphamide and Cyclosporin in Allogeneic Stem Cell Transplantation

By MedXY|Sep 30, 2025

Post-transplant cyclophosphamide plus cyclosporin significantly improves GVHD-free, relapse-free survival compared to standard prophylaxis in matched related donor stem cell transplantation.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities